Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20563862 | 0.85 | GAA (0.33) | ALDH1A1ALOX15TSHRGAATDP1 | |
| SCHEMBL12481269 | 0.78 | GAA (0.36) | ALDH1A1ALOX15TSHRGAATDP1 | |
| SCHEMBL12495771 | 0.78 | ADORA2A (0.40) | — | |
| SCHEMBL12481009 | 0.78 | GAA (0.36) | ALDH1A1ALOX15TSHRGAATDP1 | |
| SCHEMBL3944338 | 0.74 | LMNA (0.35) | ALDH1A1CYP1A2 | |
| SCHEMBL12480570 | 0.72 | GAA (0.32) | ALDH1A1ALOX15TSHRGAATDP1 | |
| SCHEMBL12481994 | 0.72 | GAA (0.32) | ALDH1A1ALOX15TSHRGAATDP1 | |
| SCHEMBL15333621 | 0.72 | GAA (0.32) | ALDH1A1ALOX15TSHRGAATDP1 | |
| SCHEMBL16446579 | 0.72 | GAA (0.32) | ALDH1A1ALOX15TSHRGAATDP1 | |
| SCHEMBL12480705 | 0.71 | PTGS2 (0.31) | ALDH1A1TSHRGAATDP1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | SHANGHAI SIMRD BIOTECHNOLOGY CO., LTD. (CN) | 2023-02-09 | — | — | US | disclosed |
| EP-4056571-A1 | TRICYCLIC DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2022-09-14 | — | — | EP | disclosed |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-05-09 | — | — | US | disclosed |
| WO-2018213777-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-22 | — | — | WO | disclosed |
| EP-2167476-B1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RES INST CHEM TECH (KR) | 2015-02-25 | — | — | EP | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-03-28 | — | — | US | disclosed |
| US-8354421-B2 | HIV reverse transcriptase inhibitors | KOREA RESEARCH INSITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-01-15 | — | — | US | disclosed |
| US-8354421-B2 | HIV reverse transcriptase inhibitors | KOREA RESEARCH INSITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-01-15 | — | — | US | disclosed |
| WO-2008016522-A2 | HIV REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-02-07 | — | — | WO | disclosed |
| EP-1159271-B1 | ANTIVIRAL 2,4-PYRIMIDINEDIONE DERIVATIVES AND PROCESS FOR THE PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2004-08-25 | — | — | EP | disclosed |
| US-6713486-B1 | HIGH ACTIVITY AGAINST WILD-TYPE AND MUTANT HIV-1; LOW TOXICITY | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2004-03-30 | — | — | US | disclosed |
| US-6452006-B1 | USED AS INTERMEDIATE IN THE SYNTHESIS OF ACTIVE COMPOUNDS WHICH ARE INHIBITORS OF HIV (HUMAN IMMUNODEFICIENCY VIRUS) REVERSE TRANSCRIPTASE | SYLACHIM (FR) | 2002-09-17 | — | — | US | disclosed |
| EP-1097143-A1 | METHOD FOR PREPARING 5-(1-METHYLETHYL)-6-(PHENYLMETHYL)PYRIMIDINE-2,4(1H,3H)-DIONE | FINORGA SA (FR) | 2001-05-09 | — | — | EP | disclosed |
| EP-0736015-B1 | ANTIVIRAL 2,4-PYRIMIDINDIONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RES INST CHEM TECH (KR) | 2001-03-07 | — | — | EP | disclosed |
| WO-2000003999-A1 | METHOD FOR PREPARING 5-(1-METHYLETHYL)-6-(PHENYLMETHYL)PYRIMIDINE-2,4(1H,3H)-DIONE | SANOFI-SYNTHELABO (FR) | 2000-01-27 | — | — | WO | disclosed |
| US-5747500-A | VIRICIDES FOR AIDS | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1998-05-05 | — | — | US | disclosed |
| EP-0736015-A1 | NOVEL ANTIVIRAL 2,4-PYRIMIDINEDIONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1996-10-09 | — | — | EP | disclosed |
| WO-1995018109-A1 | NOVEL ANTIVIRAL 2,4-PYRIMIDINEDIONE DERIVATIVES AND PROCESSES FOR THE PREPARATION THEREOF | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 1995-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130078256-A1 | NOVEL HIV REVERSE TRANSCRIPTASE INHIBITORS | POLR2E, POLR1E, POLR2H | ALDH1A1 1800/4885ALOX15 1809/4885TSHR 4786/4885 |
| US-20230044787-A1 | TRICYCLE DIHYDROIMIDAZOPYRIMIDONE DERIVATIVE, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF | LYPLAL1, LYPLA1, LYPLA2 | ALDH1A1 846/4885ALOX15 20/4885TSHR 4419/4885 |
| US-20190135793-A1 | HETEROCYCLIC INHIBITORS OF KDM5 FOR THE TREATMENT OF DISEASE | KDM5A, KDM5B, KDM5C | ALDH1A1 1687/4885ALOX15 2975/4885TSHR 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.